NewsRelease
ResearchArticle Cites Cleanascite™ for Proteome Analysis of HumanBile
MONMOUTHJUNCTION, NJ,June28, 2017 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their lipidclearance sample preparation technology for the proteomic analysis ofbile fluid.
Thecitation is:
Laohaviroj,Marut, et al. "A comparative proteomic analysis of bile forbiomarkers of cholangiocarcinoma." TumorBiology39.6 (2017): 1010428317705764.
http://journals.sagepub.com/doi/abs/10.1177/1010428317705764
Thearticle’s authors used a quantitative proteomics approach toidentify potential tumor-associated proteins in the bile fluid of sixcholangiocarcinoma patients. Cholangiocarcinoma is a primarymalignant tumor of the bile duct epithelium and is usually detectedat an advanced stage when successful treatment is no longer possible.As the tumor originates from the bile duct epithelium, bile is anideal source of tumor biomarkers for cholangiocarcinoma. In thisstudy, Isobaric labeling, coupled with Tandem mass spectrometry, wasused to quantify protein levels in the bile of cholangiocarcinoma andcontrol patients. The article states “Cleanascite™(Biotech Support Group, USA), lipid removal reagent, was added to thebile and the sample was vertically shaken for 1 h at 4°C beforecentrifugation at 10,000 × gfor 1 min.”.The authors concluded that in all, 63 proteins were significantlyincreased in cholangiocarcinoma bile compared to normal bile.Alpha-1-antitrypsin was one of the overexpressed proteins thatincreased in cholangiocarcinoma bile samples. Fecalenzyme-linked immunosorbent assay showed that alpha-1-antitrypsinlevel was able to distinguish cholangiocarcinoma patients from normalindividuals, thereby making Alpha-1-antitrypsina potential marker forearly diagnosis of cholangiocarcinoma.
“Thisreference shows the versatility of Cleanascite™to efficiently remove lipids from bile fluid, with a selectivityprofile suitable for proteome analysis using isobaric labels andLC-MS/MS reporting features.” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866